Caption Management’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-8,000
Closed -$15.4K 1663
2024
Q3
$15.4K Hold
8,000
﹤0.01% 1208
2024
Q2
$14.2K Buy
+8,000
New +$19.6K ﹤0.01% 1092
2021
Q4
Sell
-73,525
Closed -$485K 1776
2021
Q3
$485K Buy
+73,525
New +$484K 0.01% 1204
2021
Q2
Sell
-124,633
Closed -$562K 1451
2021
Q1
$562K Buy
124,633
+81,633
+190% +$448K 0.01% 786
2020
Q4
$258K Buy
+43,000
New +$283K 0.01% 816

Other funds holding LAB

Caption Management's LAB Position: Q4 2024 in Review

Caption Management sold out of Standard BioTools (LAB) in Q4 2024, closing a stake of 8,000 shares — an estimated $15.4K sold.

Caption Management first reported a position in LAB in Q4 2020 and held it in 5 quarters. The position peaked at $562K in Q1 2021. 142 funds tracked by Wall St. Rank hold LAB as of Q4 2024.

  • Caption Management reported no remaining Standard BioTools position as of Q4 2024 after selling out during the quarter.
  • Caption Management sold 8,000 Standard BioTools shares in Q4 2024, an estimated $15.4K.
  • Caption Management first reported a position in Standard BioTools in Q4 2020 and held it in 5 quarters.
  • Caption Management's Standard BioTools position peaked at $562K in Q1 2021.
  • 142 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2024.

Based on Caption Management's 13F filing for Q4 2024, filed 14 Feb 2025.